Top Markets
Coin of the day
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Rang in aandelen #30840
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Aandeelprijs
$0.089
Laatst gesynchroniseerd: 2026-08-17
Marktkapitalisatie
$15.36M
Verandering (1 dag)
50.59%
Verandering (1 jaar)
72.65%
Land
US
Handel Inhibitor Therapeutics, Inc. (INTI)

Categorie

EPS voor Inhibitor Therapeutics, Inc. (INTI)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Inhibitor Therapeutics, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Inhibitor Therapeutics, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$13.70 -
BE